


FILE

Sheet 1 of 2

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

LIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)



ATTY DOCKET NO.:

P67214US0

SERIAL NO.:

09/926,442

APPLICANT: Roger NITSCH et al.

FILING DATE:

November 5, 2001

GROUP:

Unassigned

1647

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	--------------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
PCY ↓	WO 91/19982 -	12/1991	WIPO			
	WO 94/19461 -	09/1994	WIPO			

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

PCY ↓	-	Eleni DICOU et al., "Anti-NGF Autoantibodies and NGF in Sera of Alzheimer Patients and in Normal Subjects in Relation to Age", Autoimmunity, vol. 26, pgs. 189-194, (1997).
	-	L. LORIGADOS et al., "Two-Site Enzyme Immunoassay for β NGF Applied to Human Patient Sera", Journal of Neuroscience Research, vol. 32, no. 3, pgs. 329-339, (1992).
	-	Keith A. CRUTCHER et al., "Detection of NGF-Like Activity in Human Brain Tissue: Increased Levels in Alzheimer's Disease", The Journal of Neuroscience, vol. 13, no. 6, pgs. 2540-2550, (1993).
	-	Christoph HOCK et al., "Decreased trkA Neurotrophin Receptor Expression in the Parietal Cortex of Patients with Alzheimer's Disease", Neuroscience Letters, vol. 241, pgs. 151-154, (1998).
	-	Ake SEIGER et al., "Intracranial Infusion of Purified Nerve Growth Factor to an Alzheimer Patient: The First Attempt of a Possible Future Treatment Strategy", Behavioural Brain Research, vol. 57, no. 2, pgs. 255-261, (1993).
	-	B. HOFFER et al., "Treatment Strategies for Neurodegenerative Diseases Based on Trophic Factors and Cell Transplantation Techniques", Journal of Neural Transmission, vol. 49, pgs. 1-10, (1997).
	-	Paul A. LAPCHAK, "Nerve Growth Factor Pharmacology: Application to the Treatment of Cholinergic Neurodegeneration in Alzheimer's Disease", Experimental Neurology, vol. 124, pgs. 16-20, (1993).

EXAMINER

PCY

DATE CONSIDERED

9/15/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 2

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

LIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

ATTY DOCKET NO.:

P67214US0

SERIAL NO.:

09/926,442

APPLICANT: Roger NITSCH et al.

FILING DATE:

November 5, 2001

GROUP:

Unassigned

1647

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

- Michael V. SOFRONIEW, "Nerve Growth Factor, Ageing and Alzheimer's Disease", Alzheimer's Research, vol. 2, no. 1-2, pgs. 7-13 (1996).
- Takeshi NISHIO et al., "Nerve Growth Factor Levels in Cerebrospinal Fluid are High in the Inflammatory Neurological Disorders", Clinica Chimica Acta, vol. 275, No. 1, pgs. 93-98, (1998).
- Raija LAPPALAINEN et al., "Low Levels of Nerve Growth Factor in Cerebrospinal Fluid of Children With Rett Syndrome", Journal of Child Neurology, vol. 11, no. 4, pgs. 296-300, (1996).
- G. WESKAMP et al., "An Enzyme-Linked Immunoassay for Nerve Growth Factor (NGF): A Tool for Studying Regulatory Mechanisms Involved in NGF Production in Brain and in Peripheral Tissues", vol. 48, no. 6, pgs. 1779-1786, (1987).
- Katsuhito MURASE et al., "NGF Level is not Decreased in the Serum, Brain-Spinal Fluid, Hippocampus, or Parietal Cortex of Individuals with Alzheimer's Disease", Biochemical and Biophysical Research Communications, vol. 193, no. 1, pgs. 198-203, (1993).
- Massaro, "Nerve Growth Factor (NGF) in Cerebrospinal Fluid (CSF) from Patients with Various Neurological Disorders", Journal Neurol Science, vol. 15, pgs. 105-108, (1994).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.